ストックスクリーナーアプリを入手
5.045
2.55%
0.105
Taysha Gene Therapies Inc (TSHA) 最新ニュース
Why Taysha Gene Therapies Inc. stock is rated strong buyOil Prices & Community Verified Trade Signals - newser.com
How institutional ownership impacts Taysha Gene Therapies Inc. stock2025 Biggest Moves & Weekly Watchlist for Hot Stocks - newser.com
Taysha regains full rights to TSHA-102 gene therapy for Rett - Rett Syndrome News
Chart overlay techniques for tracking Taysha Gene Therapies Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com
Candlestick signals on Taysha Gene Therapies Inc. stock todayCPI Data & Advanced Technical Analysis Signals - newser.com
Why Taysha Gene Therapies Inc. stock is favored by top institutionsQuarterly Market Summary & AI Forecast for Swing Trade Picks - newser.com
Tick level data insight on Taysha Gene Therapies Inc. volatilityQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com
Raymond James Initiates Coverage on TSHA with Strong Buy Rating - GuruFocus
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Published on: 2025-10-21 00:17:01 - newser.com
Why Taysha Gene Therapies Inc. is moving today2025 Macro Impact & Free Accurate Trade Setup Notifications - newser.com
Will Taysha Gene Therapies Inc. stock continue dividend increasesEarnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Using R and stats models for Taysha Gene Therapies Inc. forecastingJuly 2025 Levels & Risk Managed Investment Signals - newser.com
What analysts say about Taysha Gene Therapies Inc stockStock Correlation Metrics & Zero-Cost Stock Research by Professionals - earlytimes.in
Taysha Gene Therapies Eyes Volatility Amid Key Developments - StocksToTrade
Taysha Gene Therapies Faces Challenging Market Following Recent Developments - timothysykes.com
Retail Trends: Can Taysha Gene Therapies Inc. stock double in next 5 yearsJuly 2025 WrapUp & Weekly Stock Breakout Alerts - nchmf.gov.vn
Will Taysha Gene Therapies Inc. stock maintain growth story2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
Taysha Gene Therapies Faces Financial Pressure: Concerns Amid Heavy Losses - StocksToTrade
Taysha Gene Therapies Faces New Challenges Amid Market Volatility - timothysykes.com
Aug Summary: Will Taysha Gene Therapies Inc. stock maintain momentum in 2025 - nchmf.gov.vn
Weekly Earnings: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Retail Activity & Low Drawdown Trading Strategies - nchmf.gov.vn
What catalysts could drive Taysha Gene Therapies Inc. stock higherJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - nchmf.gov.vn
Taysha Gene Therapies Inc Stock Analysis and ForecastInstitutional Holding Changes & Affordable Portfolio Growth - earlytimes.in
Can Taysha Gene Therapies Inc. stock hit record highs againJuly 2025 Final Week & Growth Focused Stock Pick Reports - nchmf.gov.vn
How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment Story - Yahoo Finance
Sell Signal: Why Taysha Gene Therapies Inc. stock is seen as undervalued2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - nchmf.gov.vn
Taysha regains full rights to Rett syndrome gene therapy program By Investing.com - Investing.com Australia
Why Is Taysha Gene Therapies Stock Falling Friday? - Sahm
Taysha Gene Therapies regains full rights to TSHA-102 - MSN
Earnings visualization tools for Taysha Gene Therapies Inc.Insider Buying & AI Enhanced Trade Execution Alerts - newser.com
Bring it back home: Taysha regains gene therapy as option expires - BioWorld MedTech
I-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy - BioPharma Dive
Taysha Gene Therapies regains full rights to TSHA-102 (TSHA:NASDAQ) - Seeking Alpha
Taysha Gene Therapies (TSHA) Rating and Price Target Reaffirmed by Chardan Capital | TSHA Stock News - GuruFocus
Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034 - GlobeNewswire Inc.
Cantor Fitzgerald reiterates Overweight rating on Taysha Gene Therapies stock - Investing.com Canada
Needham Reiterates Taysha Gene Therapies (TSHA) with "Buy" Ratin - GuruFocus
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: 87% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews
Taysha Gene Therapies price target raised to $9 from $8 at BofA - MSN
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright - MSN
Taysha (TSHA) Reclaims Full Rights to Key Rett Syndrome Program - GuruFocus
Taysha Gene Therapies Regains Full Rights to TSHA-102 Program - TradingView
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 - GlobeNewswire
Taysha Regains Full Rights to TSHA-102; 100% Part A Response | TSHA Stock News - Stock Titan
Taysha Gene Therapies Hits New 52-Week High at $5.51 - Markets Mojo
TSHA 8-K: Company announces full rights to TSHA-102 for Rett - Stock Titan
0.04%
0.01%
大文字化:
|
ボリューム (24 時間):